SCHEMBL2953750

SCHEMBL2953750

Cc1ccc(-n2nc(C(C)(C)C)cc2N(OS(C)(=O)=O)C(=O)Nc2ccc(N3CCN(C(=O)c4c(F)cccc4F)CC3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.40
MAPK13 O15264 4/20 0.40
MAPK12 P53778 3/20 0.40
MAPK11 Q15759 3/20 0.40
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 3/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
MAPT P10636 2/20 0.37
PTK2 Q05397 2/20 0.37
MAPK9 P45984 1/20 0.37
NPC1 O15118 1/20 0.36
SLC6A9 P48067 1/20 0.36
PTK2B Q14289 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603475 0.91 MAPK14 (0.40) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL3174404 0.87 MAPK14 (0.38) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL4602880 0.87 MAPK14 (0.43) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL4602876 0.86 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL4602779 0.86 MAPK13 (0.45) MAPK14MAPK13MAPK12MAPK11CA12
SCHEMBL3170652 0.84 MAPK14 (0.36) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL4602536 0.83 FAAH (0.38) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL3392562 0.83 KMT2A (0.36) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL2953747 0.82 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11PTK2
SCHEMBL3388858 0.81 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767674-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2010-08-03 US disclosed
US-20080306068-A1 Suppression cytokines, tumor necrosis factor ELI LILLY AND COMPANY (US) 2008-12-11 US disclosed
EP-1761520-B1 KINASE INHIBITORS LILLY CO ELI (US) 2008-07-09 EP disclosed
EP-1761520-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-03-14 EP disclosed
WO-2006009741-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306068-A1 Suppression cytokines, tumor necrosis factor TNF, TNFRSF1A, IL2 MAPK14 436/4885MAPK13 576/4885MAPK12 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.